Cabotegravir/rilpivirine (Cabenuva) vs Etravirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Etravirine · Intelence

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00254046 · Phase 3 · completed

Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.

Reported efficacy

Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)

Result source: NCT00254046

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCabotegravir/​rilpivirine (Cabenuva)Etravirine
HIV-1 RNA below 50 copies/mL (week 48)94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
56% vs 39%a+17 vs placebowk 24NCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311—Not posted · NCT00255099
CD4 count, change (week 48)270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
—Not posted · NCT00255099

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
Etravirine
56% vs 39%a+17 vs placebowk 24NCT00254046

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
Etravirine
—Not posted · NCT00255099

CD4 count, change (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
Etravirine
—Not posted · NCT00255099
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Cabotegravir/rilpivirine (Cabenuva): 7 of 7 rows · Etravirine: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)
Rows use multiple source trials
Etravirine
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
351 cells/uL @ 192wk30 mga,b,c
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
342.3 cells/uL @ 192wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
300.8 cells/uL @ 192wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
149.5 cells/uL @ 192wkb,c
NCT00128830 · Phase 2 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.215 log @ 324wk30 mga,b,c,d
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
-2.438 log @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.488 log @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-1.53 log @ 48wkb,c,d
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
87% (n=430) @ 52wke,b,c,f
NCT04399551 · Phase 3 · registry result, not featured evidence
45.5% (n=22) @ 48wk400/100 mga,e,b,c,f
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
50% (n=22) @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
13.6%g
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestoneg
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
20.3%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
36%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
40%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
24.8%
NCT00665847 · Phase 2 · registry result, not featured evidence
20.3%
NCT00903682 · Phase 2 · registry result, not featured evidence
34.1%
NCT00128830 · Phase 2 · registry result, not featured evidence
5%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
—g
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
6.7%g
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
3.8%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
4%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
8%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
7.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
7.6%
NCT00903682 · Phase 2 · registry result, not featured evidence
4.7%
NCT00128830 · Phase 2 · registry result, not featured evidence
—Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
—
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Serious AEs
0%g
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
10%g
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
15.2%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
8%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
16%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
5%
NCT00665847 · Phase 2 · registry result, not featured evidence
13.9%
NCT00903682 · Phase 2 · registry result, not featured evidence
21.8%
NCT00128830 · Phase 2 · registry result, not featured evidence
25%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
50%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
0%200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
20%
NCT01427504 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
g
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
g
cough 2.8%
upper respiratory tract infection 2.8%
pregnancy 2.2%
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
400 mg once daily
elevated level of transaminase 11.4%
hyperbilirubinemia 7.6%
hyperlipidemia 7.6%
NCT00959894 · Phase 2 · registry result, not featured evidence
400/100 mg
cough 16%
headache 12%
influenza 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
300/100 mg
cough 20%
nausea 16%
blood bilirubin increased 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 26.7%
diarrhoea 15.8%
cough 12.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
nasopharyngitis 21.5%
headache 16.5%
diarrhoea 10.1%
NCT00903682 · Phase 2 · registry result, not featured evidence
diarrhoea 17.5%
upper respiratory tract infection 17.1%
sinusitis 11.4%
NCT00128830 · Phase 2 · registry result, not featured evidence
blood bicarbonate decreased 90%
blood sodium decreased 70%
nasal congestion 70%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
cough 100%
nasal congestion 100%
rhinorrhoea 100%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
200 mg + 200 mg
headache 18.8%
toothache 12.5%
diarrhoea 6.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
200 mg + 600/100 mg + 200 mg
rash maculo-papular 20%
scleral hyperaemia 20%
headache 13.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
headache 14.3%
constipation 10.7%
diarrhea 7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
breast tenderness 66.7%
diarrhea 11.1%
headache 11.1%
NCT01625169 · Phase na · registry result, not featured evidence · combination
altered taste 64%
headache 16%
rash 16%
NCT01427504 · Phase na · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 324 weeks versus 48 weeks.
  5. eTrial phases differ: Phase 3 versus Phase 2.
  6. fAssessment timepoints differ: 52 weeks versus 48 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Ge50 Copies 0% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
1.1% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
2.2% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
HIV-1 RNA LT 50 Copies 93.9% (n=115) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04001803 · Phase 3 · registry result, not featured evidence
show 25 more results
94.8% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
91.3% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
90.4% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
87.8% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
96% (n=115) @ 4.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
98% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 56.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 65wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 69.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 78wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 82.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 91wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 95.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 104wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 108.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 117wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 121.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 130wk
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
Virologic Failure 0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
event count · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 6 more results
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
1.7% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
1.1% (n=90) vs 0% (n=7) DTG + RPV*Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
HIV-1 RNA Less Than 50 Copies 99% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
95% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q8W
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination

+ 168 further endpoints in the CSV export.

Etravirine

HIV-1 RNA Less Than 50 Copies 0.87% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.77% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.71% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 0.89% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.82% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.77% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
CD4 46 count @ 4wk400/100 mg
absolute change · count
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
72 count @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
83 count @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
132 count @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
55 count @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
31 count @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
54 count @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
105 count @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Virological Response 50 Copies Snapshot 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA -1.8 copies/mL @ 4wk400/100 mg
absolute change · copies/mL
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
-2 copies/mL @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.9 copies/mL @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.7 copies/mL @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Time to Viral Suppression 2.5 months400/100 mg
time to event · months
No placebo or comparator arm
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 76 days as posted
show 1 more result
2.33 months*300/100 mg
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 71 days as posted
Time to Virologic Failure NA months400/100 mg
time to event · months
No placebo or comparator arm
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
10.45 months*300/100 mg
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 318 days as posted
Virologic 52.5% (n=101) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies Per 75.9% (n=79) vs 74.4% (n=78) Efavirenz @ 48wk
event count · % of participants
Maintenance
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 60 Number of participants as posted
show 1 more result
81% (n=79) vs 79.5% (n=78) Efavirenz @ 48wk*
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 64 Number of participants as posted
CD4 69.96 vs 72.45 Efavirenz count @ 2wk
absolute change · count
Induction
NCT00903682 · Phase 2 · registry result, not featured evidence
show 2 more results
128.14 vs 121.62 Efavirenz count @ 6wk
NCT00903682 · Phase 2 · registry result, not featured evidence
143.24 vs 151.46 Efavirenz count @ 12wk
NCT00903682 · Phase 2 · registry result, not featured evidence
CD4 182.01 vs 174.08 Efavirenz count @ 24wk
absolute change · count
Maintenance
NCT00903682 · Phase 2 · registry result, not featured evidence
show 2 more results
213.45 vs 180.18 Efavirenz count @ 36wk
NCT00903682 · Phase 2 · registry result, not featured evidence
205.11 vs 221.39 Efavirenz count @ 48wk
NCT00903682 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 58% (n=181) @ 96wk
responder rate · % of participants
No placebo or comparator arm
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 105 Participants as posted
show 1 more result
70.4% (n=98) @ 192wk*
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 69 Participants as posted

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Etravirine's landscape